Received Feb 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | YZ9CY | — |
patient received an extra 3rd dose of Shingrix by accident back on February 8th 2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 64-year-old male patient who received Herpes zoster (Shingrix) (batch number YZ9CY) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 28-FEB-2022 with batch number TM449) and Shingrix (received 2nd dose on 29-APR-2022 with batch number 445XD). On 08-FEB-2025, the patient received the 3rd dose of Shingrix. On 08-FEB-2025, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: patient received an extra 3rd dose of Shingrix by accident back on February 8th 2025). The outcome of the extra dose administered was unknown. Additional Information: GSK Receipt Date: 13-FEB-2025 The pharmacist mentioned that a patient received an extra 3rd dose of Shingrix by accident back on 8th February 2025 which led to extra dose administration. The patient received 2 prior Shingrix doses on 29th April 2022 and 28th February 2022. Expiration dates were unknown by reporter.